[go: up one dir, main page]

EA021248B1 - Pharmaceutical composition having vasoconstricting, anticongestant, anti-inflammatory activity (embodiments) - Google Patents

Pharmaceutical composition having vasoconstricting, anticongestant, anti-inflammatory activity (embodiments) Download PDF

Info

Publication number
EA021248B1
EA021248B1 EA201200363A EA201200363A EA021248B1 EA 021248 B1 EA021248 B1 EA 021248B1 EA 201200363 A EA201200363 A EA 201200363A EA 201200363 A EA201200363 A EA 201200363A EA 021248 B1 EA021248 B1 EA 021248B1
Authority
EA
Eurasian Patent Office
Prior art keywords
pharmaceutical composition
carbon isotopes
anticongestant
vasoconstricting
naphazoline
Prior art date
Application number
EA201200363A
Other languages
Russian (ru)
Other versions
EA201200363A1 (en
Inventor
Анастасия Геннадьевна ЧЕЛЯЕВА
Владимир Павлович ЛОБКО
Original Assignee
Ооо "Фармацевтическая Компания "Славянская Аптека"
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ооо "Фармацевтическая Компания "Славянская Аптека" filed Critical Ооо "Фармацевтическая Компания "Славянская Аптека"
Priority to EA201200363A priority Critical patent/EA021248B1/en
Publication of EA201200363A1 publication Critical patent/EA201200363A1/en
Publication of EA021248B1 publication Critical patent/EA021248B1/en

Links

Landscapes

  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

The invention relates to the field of the pharmaceutical industry and medicine and can be used for the production and application of pharmaceutical compositions having vasoconstricting, anticongestant, anti-inflammatory activity in cases of acute rhinitis, inflammatory processes of the maxillary sinuses, nosebleeds and conjunctivitis. The aim of the invention consists in producing a pharmaceutical composition on the basis of the preparation naphazoline by introducing mineral substances into the pharmaceutical composition, and substitutingC carbon isotopes withC carbon isotopes in the pharmaceutical composition.

Description

(57) Изобретение относится к области фармацевтической промышленности и медицине, может быть использовано для создания и применения фармацевтических составов, обладающих сосудосуживающим, антиконгестивным, противовоспалительным действием при острых ринитах, воспалительных процессах гайморовых полостей носа, носовых кровотечениях, конъюнктивитах. Задачей изобретения является создание фармацевтического состава на базе препарата нафазолин за счет введения в фармацевтический состав минеральных веществ, замещения в фармацевтическом составе изотопов углерода 12С на изотопы углерода 13С.(57) The invention relates to the field of pharmaceutical industry and medicine, can be used to create and use pharmaceutical formulations with vasoconstrictive, anti-congestive, anti-inflammatory effects in acute rhinitis, inflammatory processes of the maxillary sinus cavities, nosebleeds, conjunctivitis. The objective of the invention is to create a pharmaceutical composition based on the drug naphazoline by introducing into the pharmaceutical composition of mineral substances, substitution in the pharmaceutical composition of carbon isotopes 12 With carbon isotopes 13 C.

021248 Β1021248 Β1

Claims (3)

1. Фармацевтический состав - раствор, содержащий нафазолин, отличающийся тем, что содержит минеральные вещества при следующем соотношении компонентов, мг/л:1. The pharmaceutical composition is a solution containing naphazoline, characterized in that it contains minerals in the following ratio of components, mg / l: нафазолин 0.1 ' 10 1 2 3 - 10 10 3; кальций 0.1 - 125.50;naphazoline 0.1 '10 1 2 3 - 10 10 3 ; calcium 0.1 - 125.50; магний калийmagnesium potassium 0.065 - 160.0; 0.02-27.7, и при этом фармацевтический состав обладает сосудосуживающим, антиконгестивным, противовоспалительным действием.0.065 - 160.0; 0.02-27.7, and the pharmaceutical composition has a vasoconstrictive, anti-congestive, anti-inflammatory effect. 2. Фармацевтический состав - раствор, содержащий нафазолин, отличающийся тем, что дополнительно содержит минеральные вещества при следующем соотношении компонентов, мг/л:2. The pharmaceutical composition is a solution containing naphazoline, characterized in that it additionally contains mineral substances in the following ratio of components, mg / l: нафазолин 0.1 ' 103 - 10'10 3;naphazoline 0.1 '10 3 - 3 10'10; кальций 0.1 - 125.50;calcium 0.1 - 125.50; магний 0.065 -160.0;magnesium 0.065 -160.0; калий 0.02-27.7, при этом фармацевтический состав содержит изотопы углерода 13С и отношение пС=03С0С, где пС - отношение количества изотопов углерода 13С к общему количеству углерода в фармацевтическом составе;potassium 0.02-27.7, while the pharmaceutical composition contains 13 C carbon isotopes and the ratio pC = 0 3 C0C, where pC is the ratio of 13 C carbon isotopes to the total amount of carbon in the pharmaceutical composition; - 17 021248- 17 021248 Ν13Ο - количество изотопов углерода 13С в фармацевтическом составе;Ν 13 Ο - the amount of carbon isotopes 13 C in the pharmaceutical composition; N0 - общее количество изотопов углерода в фармацевтическом составе, составляет величину от 0.005 до 0.75, и при этом фармацевтический состав обладает сосудосуживающим, антиконгестивным, противовоспалительным действием.N0 is the total amount of carbon isotopes in the pharmaceutical composition, ranging from 0.005 to 0.75, and the pharmaceutical composition has a vasoconstrictive, anti-congestive, anti-inflammatory effect. 3. Фармацевтический состав по любому из пп.1, 2, отличающийся тем, что значение рН составляет величину от 4 до 7.3. The pharmaceutical composition according to any one of claims 1, 2, characterized in that the pH value is from 4 to 7. тйИ 2500. -2000!5оо•1000X 5ОО.TyI 2500. -2000! 5oo • 1000X 5OO. .:-./0-О.: -. / 0-O Фиг. 1FIG. one - 18 021248- 18 021248 Фиг. 4FIG. 4 - 19 021248- 19 021248 - 20 021248- 20 021248 - 21 021248- 21 021248 - 22 021248- 22 021248
EA201200363A 2012-03-26 2012-03-26 Pharmaceutical composition having vasoconstricting, anticongestant, anti-inflammatory activity (embodiments) EA021248B1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EA201200363A EA021248B1 (en) 2012-03-26 2012-03-26 Pharmaceutical composition having vasoconstricting, anticongestant, anti-inflammatory activity (embodiments)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EA201200363A EA021248B1 (en) 2012-03-26 2012-03-26 Pharmaceutical composition having vasoconstricting, anticongestant, anti-inflammatory activity (embodiments)

Publications (2)

Publication Number Publication Date
EA201200363A1 EA201200363A1 (en) 2013-09-30
EA021248B1 true EA021248B1 (en) 2015-05-29

Family

ID=49232831

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201200363A EA021248B1 (en) 2012-03-26 2012-03-26 Pharmaceutical composition having vasoconstricting, anticongestant, anti-inflammatory activity (embodiments)

Country Status (1)

Country Link
EA (1) EA021248B1 (en)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2156087C1 (en) * 1999-11-25 2000-09-20 Товарищество с ограниченной ответственностью Фирма "Электронная медицина" Biologically active addition
US20030065029A1 (en) * 1997-06-18 2003-04-03 Cosmo Research Institute, Cosmo Oil Co., Ltd. Agent for diagnosing and treating malignant tumors
RU2238081C1 (en) * 2003-07-14 2004-10-20 Открытое акционерное общество "Московская фармацевтическая фабрика" Agent with anti-congestive effect

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030065029A1 (en) * 1997-06-18 2003-04-03 Cosmo Research Institute, Cosmo Oil Co., Ltd. Agent for diagnosing and treating malignant tumors
RU2156087C1 (en) * 1999-11-25 2000-09-20 Товарищество с ограниченной ответственностью Фирма "Электронная медицина" Biologically active addition
RU2238081C1 (en) * 2003-07-14 2004-10-20 Открытое акционерное общество "Московская фармацевтическая фабрика" Agent with anti-congestive effect

Also Published As

Publication number Publication date
EA201200363A1 (en) 2013-09-30

Similar Documents

Publication Publication Date Title
MA33044B1 (en) PHARMACEUTICAL COMPOSITION CONTAINING GLUCOPYRANOSYL DIPHENYLMETHANE DERIVATIVES, ITS GALENIC DOSAGE FORM, PREPARATION METHOD AND USES FOR ENHANCED GLYCEMIC REGULATION IN PATIENT
EA201291034A1 (en) APTAMERS TO β-NGF AND THEIR APPLICATION IN THE TREATMENT OF B-NGF-MEDIATED DISEASES AND DISORDERS
EA201171285A1 (en) NEW TECHNOLOGY OF MANUFACTURING DICLOFENAKA
EA201171284A1 (en) NEW TECHNOLOGY OF MANUFACTURING OF PRAXEN
MX2013014843A (en) Oxazepines as ion channel modulators.
EA201171286A1 (en) NEW TECHNOLOGY OF INDOMETACINE MANUFACTURING
EA201100896A1 (en) COMPOSITION INTENDED FOR SUCKING NICOTINE FROM THE FATAL CAVITY WITH THE PURPOSE TO STOP SMOKING
SG10201902353UA (en) Capturing specific nucleic acid materials from individual biological cells in a micro-fluidic device
EA201100921A1 (en) COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND METHODS OF THEIR APPLICATION IN THE TREATMENT OF MATERIAL EXCHANGE DISORDERS
EA201201658A1 (en) DERIVATIVES OF PIPERIDINE AND THEIR APPLICATION FOR THE TREATMENT OF METABOLIC DISORDERS
MX2016005668A (en) Crystalline forms of therapeutic compounds and uses thereof.
EA201171283A1 (en) NEW TECHNOLOGY OF MELOXICAM MANUFACTURE
EA201490152A1 (en) TRPM8 ANTAGONISTS AND THEIR APPLICATION IN TREATMENT
FR2981934B1 (en) NOVEL DI-SUBSTITUTED DIAMINO-3,4-CYCLOBUTENE-3-DIONE-1,2 COMPOUNDS USEFUL IN THE TREATMENT OF CHEMOKINE MEDIATED PATHOLOGIES.
MA35455B1 (en) (wo2013045407) derivatives of estra-1,3,5 (10), 16-tetraene-3-carboxamide, process for their manufacture, pharmaceutical preparations containing these substances and their use in the manufacture of medicaments
EA201491281A1 (en) COMPOSITION IN THE FORM OF DRY POWDER CONTAINING CORTICOSTEROIDS AND β-ADRENERGIC MEDICINE FOR INTRODUCTION BY INHALATION
EA201391379A1 (en) PHARMACEUTICAL COMPOSITION FOR TREATING DISEASES IN THE ORAL CAVITY CONTAINING REBAMIPID
AR125850A2 (en) TOPICAL PHARMACEUTICAL COMPOSITION, PRODUCTION PROCESS OF THE TOPICAL PHARMACEUTICAL COMPOSITION, USE OF THE TOPICAL PHARMACEUTICAL COMPOSITION AND METHOD OF TOPICAL TREATMENT OF PSORIASIS, ATOPIC DERMATITIS OR CHRONIC ECZEMAS
MX342976B (en) Use of melatonin for treating and/or preventing mucositis.
RU2019110980A (en) PHARMACEUTICAL COMPOSITIONS CONTAINING A 15-HEPC AND METHODS FOR TREATING ASTHMA AND LUNG DISEASES WITH THEIR APPLICATION
FR2981936B1 (en) NOVEL DI-SUBSTITUTED DIAMINO-3,4-CYCLOBUTENE-3-DIONE-1,2 COMPOUNDS USEFUL IN THE TREATMENT OF CHEMOKINE MEDIATED PATHOLOGIES.
EA021248B1 (en) Pharmaceutical composition having vasoconstricting, anticongestant, anti-inflammatory activity (embodiments)
EA021233B1 (en) Pharmaceutical composition having vasoconstricting, anticongestant, anti-inflammatory activity (embodiments)
BR112015005876A2 (en) low melting propionic acid derived particles for use in oral dosage forms
EA201592297A1 (en) AGOMELATIN COMPOSITIONS CONTAINING AGOMELATIN IN THE FORM OF CRYSTALS

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM RU